Cullinan Oncology, Inc.·4

Feb 21, 6:57 PM ET

Savill Corrine 4

4 · Cullinan Oncology, Inc. · Filed Feb 21, 2023

Insider Transaction Report

Form 4
Period: 2023-02-17
Savill Corrine
Chief Business Officer
Transactions
  • Award

    Common Stock

    2023-02-17+20,500170,115 total
  • Award

    Stock Option (Right to Buy)

    2023-02-17+41,00041,000 total
    Exercise: $11.34Exp: 2033-02-16Common Stock (41,000 underlying)
Footnotes (2)
  • [F1]The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
  • [F2]The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Documents

2 files